DrugPatentWatch Database Preview
Investigational Drug Information for Huperzine A
Email this page to a colleague
What is the development status for investigational drug Huperzine A?
Huperzine A is an investigational drug.
There have been 13 clinical trials for Huperzine A.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Supernus Pharmaceuticals, Inc., Biscayne Neurotherapeutics, Inc., and Alzheimer's Disease Cooperative Study (ADCS).
Summary for Huperzine A
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,110 |
| WIPO Patent Applications | 824 |
| Japanese Patent Applications | 344 |
| Clinical Trial Progress | Phase 2 (2009-12-01) |
| Vendors | 102 |
Recent Clinical Trials for Huperzine A
| Title | Sponsor | Phase |
|---|---|---|
| Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects | Supernus Pharmaceuticals, Inc. | Early Phase 1 |
| Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage | Jiangsu Famous Medical Technology Co., Ltd. | Phase 4 |
| Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging | Shanghai Mental Health Center | Phase 4 |
Clinical Trial Summary for Huperzine A
Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A
US Patents for Huperzine A
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
